Combining methionine‐PET and MRI fluid‐attenuated inversion‐recovery mismatch to determine glioma molecular subtype
暂无分享,去创建一个
J. Shinoda | T. Iwama | Y. Muragaki | H. Yano | Y. Ikegame | M. Kumagai | Nobutoshi Kumagai | K. Ohmura
[1] T. Iwaya,et al. PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma , 2022, Clinical nuclear medicine.
[2] Yuichi Fujita,et al. NI-7 Diffusion-weighted imaging for monitoring acute response and recurrence after photodynamic therapy in malignant gliomas , 2021, Neuro-oncology Advances.
[3] R. Taipa,et al. T2-FLAIR mismatch sign: a roadmap of pearls and pitfalls. , 2021, The British journal of radiology.
[4] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[5] M. Scorsetti,et al. Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study , 2021, Journal of clinical medicine.
[6] N. Nakayama,et al. Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. , 2020, Journal of neurosurgery.
[7] S. Thust,et al. Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review , 2020, Neuroradiology.
[8] Zhi-rui Zhou,et al. A Nomogram Modeling 11C-MET PET/CT and Clinical Features in Glioma Helps Predict IDH Mutation , 2020, Frontiers in Oncology.
[9] A. Shinomiya,et al. Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification , 2020, EJNMMI Research.
[10] Sohil H. Patel,et al. 'Real world' use of a highly reliable imaging sign: 'T2-FLAIR mismatch' for identification of IDH mutant astrocytomas. , 2020, Neuro-oncology.
[11] S. Heiland,et al. T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology , 2020, Neuro-oncology advances.
[12] P. Kerezoudis,et al. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. , 2019, Neurosurgical focus.
[13] Sohil H. Patel,et al. T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project , 2017, Clinical Cancer Research.
[14] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[15] Pankaj Pathak,et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. , 2013, Neuro-oncology.
[16] Akira Matsumura,et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing , 2011, Brain Tumor Pathology.
[17] Y. Muragaki,et al. Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline Positron-Emission Tomography , 2008, American Journal of Neuroradiology.
[18] I Kapouleas,et al. Registration of three-dimensional MR and PET images of the human brain without markers. , 1991, Radiology.
[19] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[20] J. Mukherjee,et al. 11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas , 2007, Molecular Imaging and Biology.